Novo will harness Anthropic’s AI assistant Claude to accelerate research and development (R&D) activities, as the drugmaker looks to regain its once-dominant position at the fro ...

Sling is racing to market the first oral IGF-1R blocker, which would likely provide competition to Amgen’s Tepezza.

Definium Therapeutics plans to submit an NDA for LSD-based psychedelic, DT120 in generalised anxiety disorder (GAD) during H1 2027.

The HHS appoints these leadership positions as it looks to “reform” the FDA, which has recently faced a high turnover in leadership.

The FDA has granted accelerated approval to AstraZeneca's Etcamah (camizestrant), used with a CDK 4/6 inhibitor, for breast cancer.

ABEC is to open a new manufacturing facility in Wilson, North Carolina, US, expanding its network for biopharmaceutical process equipment.

Share prices tumbled last week after a key asset from Novartis’ $12bn Avidity deal fumbled in a Phase III trial.

A survey of 175 pharma executives highlights an increasing reluctance to launch in lower-value markets, alongside a heightened focus on RWE.

Cell and gene therapies are fuelling new possibilities for rare diseases, turning a field defined by unmet need into one of the industry’s most dynamic areas of innovation.

Biotechs and investors are increasingly altering their strategies amid changes in the development and commercial landscape.

At ERS 2026, investigators reported their findings from their review of the Oxford Asthma Attack Risk Scale Meta-Analysis (ORACLE2).

As regulatory enforcement surges, life science manufacturers must shift away from paper-based systems to ensure compliance.